Kristin Gustafson
Keine laufenden Positionen mehr
Profil
Kristin Gustafson is the founder of Chemo101, Inc. She worked as Senior Vice President-Human Resources & Facilities at Intercept Pharmaceuticals, Inc., Kite Pharma, Inc., and Turnstone Biologics Corp.
She was also the Chief Human Resources Officer at Mirati Therapeutics, Inc. Gustafson received an undergraduate degree from the University of Wisconsin.
Ehemalige bekannte Positionen von Kristin Gustafson
Unternehmen | Position | Ende |
---|---|---|
MIRATI THERAPEUTICS | Human Resources Officer | 23.01.2024 |
Chemo101, Inc. | Founder | - |
INTERCEPT PHARMACEUTICALS, INC. | Human Resources Officer | - |
KITE PHARMA INC | Corporate Officer/Principal | - |
TURNSTONE BIOLOGICS CORP. | Human Resources Officer | - |
Ausbildung von Kristin Gustafson
University of Wisconsin | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
TURNSTONE BIOLOGICS CORP. | Health Technology |
Private Unternehmen | 3 |
---|---|
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
Chemo101, Inc. |